Search | IOVS | ARVO Journals

Showing 1 – 20 of 28

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2022

An Optimized, Patient-Customized Grid Maximizes Microperimetry Readouts in Geographic Atrophy: Evaluation of Average Threshold Test-Retest Reliability

Masara Issa; Amber Lewis; Kameran Lashkari; Karl Csaky; Francisco J. Lopez

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):4544 – F0458. doi:

ARVO Annual Meeting Abstract June 2021

A Retrospective Analysis: Visual Field Progression and Visual Acuity following Administration of Brimonidine Drug Delivery System

Ellen Brossart; Bill Bunnell; Tudor Tepelus; Michelle Y. Chen; Francisco J Lopez

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):3372. doi:

ARVO Annual Meeting Abstract June 2021

Cytoprotective Effects of Brimonidine in an Induced Pluripotent Stem Cell (iPSC)-Derived Retinal Pigment Epithelium (RPE) Model of Age-Related Macular Degeneration (AMD)

Lori-Ann Christie; Ruchi Sharma; Malika Nimmagadda; Davide Ortolan; Genqing Liang; Kiyoharu Joshua Miyagishima; Mitalee Tamhane; Mike Ly; William Change; Richard Graham; Shaoxin Feng; Francisco J Lopez; Brenda Smith; Kapil Bharti

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):195. doi:

ARVO Annual Meeting Abstract June 2021

Profile of vascular permeability factors in aqueous humor of diabetic macular edema

Matthew Mason; Kameran Lashkari; Sveti Ugarte; Lori-Ann Christie; Gerry Rodrigues; Francisco J Lopez

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1068. doi:

ARVO Annual Meeting Abstract June 2020

Limitations of Lesion Perimeter for Measurement of Geographic Atrophy Progression

Alice Blaj; Lewis Amber; Kevin Kerr; Werner Schmidt; Francisco J. Lopez

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):2987. doi:

ARVO Annual Meeting Abstract July 2019

Phase 2b Study of Brimonidine DDS: Potential Novel Treatment for Geographic Atrophy

William R Freeman; Francesco Bandello; Eric H Souied; Robyn H Guymer; Sunir Garg; Fred Kuanfu Chen; Ryan M Rich; Frank G Holz; Yan Li; Kevin Kerr; Francisco J. Lopez

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):971. doi:

ARVO Annual Meeting Abstract July 2018

A Novel Iridocorneal Angle Measurement Technique: Assessment of Inter- and Intra-Scorer Variability

Ashley Nguyen; Quoc Ho; Francisco J. Lopez; Kevin Kerr; Susan Schneider; Jingyuan Yang; Margot L Goodkin; Michelle Y. Chen

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1699. doi:

ARVO Annual Meeting Abstract July 2018

Identification of Novel Biomarkers in Geographic Atrophy using Wide Spectrum Multiplexing

Kameran Lashkari; Gianna C Teague; Ursula Beattie; Megan McLaughlin; Francisco J. Lopez

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):2417. doi:

ARVO Annual Meeting Abstract July 2018

Identification of Key Vitreous Biomarkers in Diabetic Macular Edema Associated with Proliferative Diabetic Retinopathy

Gianna C Teague; Namrata Nandakumar; Francisco J. Lopez; Kameran Lashkari

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):4834. doi:

ARVO Annual Meeting Abstract July 2018

Diabetic Macular Ischemia: Angio-OCT measurement compared to fluorescein angiography

JOSE FRANCISCO VALDEZ VALDEZ LOPEZ

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):2799. doi:

ARVO Annual Meeting Abstract June 2017

Brimonidine Drug Delivery System (DDS) Generation 1 in patients with geographic atrophy: Post-hoc analysis of a phase 2 study

Baruch D Kuppermann; Sunil S Patel; David S Boyer; Albert J Augustin; William R Freeman; Thomas Kim; Kevin Kerr; Francisco J Lopez; Susan Schneider

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1924. doi:

ARVO Annual Meeting Abstract June 2017

A systematic approach to statistical evaluation of geographic atrophy clinical studies

Thomas Kim; Alan Mitchell; Jeen Liu; Kevin Kerr; Francisco J Lopez; Susan Schneider

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2341. doi:

ARVO Annual Meeting Abstract June 2017

Comparison of Three Baseline Measures to Predict Geographic Atrophy Progression Rate in Clinical Studies

Quoc Ho; Mia Mackowski; Kevin Kerr; Francisco J Lopez; Susan Schneider

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2343. doi:

ARVO Annual Meeting Abstract June 2017

Analysis of Vitreous Biomarkers in Proliferative Diabetic Retinopathy and Macular Edema

Namrata Nandakumar; Francisco J Lopez; Gianna C Teague; Kameran Lashkari

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):5807. doi:

ARVO Annual Meeting Abstract September 2016

COMPLEMENT FACTOR I BIOACTIVITY: A POTENTIAL BIOMARKER FOR ANTI-AMYLOID BETA TREATMENT IN AGE-RELATED MACULAR DEGENERATION/GEOGRAPHIC ATROPHY

Francisco J Lopez; Hong Chen; Yong-Qing Lin; Sanjay Kumar; Megan M McLaughlin

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2129. doi:

ARVO Annual Meeting Abstract September 2016

Are Systemic Levels of Amyloid β Altered in Patients with Geographic Atrophy?

Kameran Lashkari; Francisco J Lopez; Gianna C Teague; Sanjay Kumar; Megan M McLaughlin

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12) doi:

ARVO Annual Meeting Abstract September 2016

Evaluation of Vitreous Factor in Proliferative Diabetic Retinopathy

Namrata Nandakumar; Gianna C Teague; Francisco J Lopez; Walter Johnson; Kameran Lashkari

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):5452. doi:

Physiology and Pharmacology June 2016

Blockage of PI3K/mTOR Pathways Inhibits Laser-Induced Choroidal Neovascularization and Improves Outcomes Relative to VEGF-A Suppression Alone

PDF

Jie Ma; Yu Sun; Francisco J. López; Peter Adamson; Edit Kurali; Kameran Lashkari
TAGS: 1-phosphatidylinositol 3-kinase, aflibercept, choroidal neovascularization, lasers, mtor serine-threonine kinases, vascular endothelial growth factor a
Invest. Ophthalmol. Vis. Sci.. 2016; 57(7):3138-3144. doi: https://doi.org/10.1167/iovs.15-18795

Letters to the Editor December 2015

Author Response: The Role of IL-18 in the Treatment of AMD

PDF

Sarah L. Doyle; Francisco J. López; Peter Humphries; Peter Adamson; Matthew Campbell
TAGS: interleukin-18
Invest. Ophthalmol. Vis. Sci.. 2015; 56(13):8237-8238. doi: https://doi.org/10.1167/iovs.15-18714

Biochemistry and Molecular Biology August 2015

IL-18 Immunotherapy for Neovascular AMD: Tolerability and Efficacy in Nonhuman Primates

PDF

Sarah L. Doyle; Francisco J. López; Lucia Celkova; Kiva Brennan; Kelly Mulfaul; Ema Ozaki; Paul F. Kenna; Edit Kurali; Natalie Hudson; Teresa Doggett; Thomas A. Ferguson; Peter Humphries; Peter Adamson; Matthew Campbell
TAGS: exudative age-related macular degeneration, immunotherapy, interleukin-18, primates
Invest. Ophthalmol. Vis. Sci.. 2015; 56(9):5424-5430. doi: https://doi.org/10.1167/iovs.15-17264

Includes: Supplemental Content

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

An Optimized, Patient-Customized Grid Maximizes Microperimetry Readouts in Geographic Atrophy: Evaluation of Average Threshold Test-Retest Reliability

A Retrospective Analysis: Visual Field Progression and Visual Acuity following Administration of Brimonidine Drug Delivery System

Cytoprotective Effects of Brimonidine in an Induced Pluripotent Stem Cell (iPSC)-Derived Retinal Pigment Epithelium (RPE) Model of Age-Related Macular Degeneration (AMD)

Profile of vascular permeability factors in aqueous humor of diabetic macular edema

Limitations of Lesion Perimeter for Measurement of Geographic Atrophy Progression

Phase 2b Study of Brimonidine DDS: Potential Novel Treatment for Geographic Atrophy

A Novel Iridocorneal Angle Measurement Technique: Assessment of Inter- and Intra-Scorer Variability

Identification of Novel Biomarkers in Geographic Atrophy using Wide Spectrum Multiplexing

Identification of Key Vitreous Biomarkers in Diabetic Macular Edema Associated with Proliferative Diabetic Retinopathy

Diabetic Macular Ischemia: Angio-OCT measurement compared to fluorescein angiography

Brimonidine Drug Delivery System (DDS) Generation 1 in patients with geographic atrophy: Post-hoc analysis of a phase 2 study

A systematic approach to statistical evaluation of geographic atrophy clinical studies

Comparison of Three Baseline Measures to Predict Geographic Atrophy Progression Rate in Clinical Studies

Analysis of Vitreous Biomarkers in Proliferative Diabetic Retinopathy and Macular Edema

COMPLEMENT FACTOR I BIOACTIVITY: A POTENTIAL BIOMARKER FOR ANTI-AMYLOID BETA TREATMENT IN AGE-RELATED MACULAR DEGENERATION/GEOGRAPHIC ATROPHY

Are Systemic Levels of Amyloid β Altered in Patients with Geographic Atrophy?

Evaluation of Vitreous Factor in Proliferative Diabetic Retinopathy

Blockage of PI3K/mTOR Pathways Inhibits Laser-Induced Choroidal Neovascularization and Improves Outcomes Relative to VEGF-A Suppression Alone

Author Response: The Role of IL-18 in the Treatment of AMD

IL-18 Immunotherapy for Neovascular AMD: Tolerability and Efficacy in Nonhuman Primates

To View More...

You must be signed into an individual account to use this feature.